The US deferasirox market is supported by the ongoing need for effective iron chelation therapy among patients experiencing chronic iron overload associated with conditions such as thalassemia, sickle cell disease, and other transfusion-dependent disorders. As an oral chelation option, deferasirox offers a convenient approach to long-term iron management and can support treatment adherence...